Latest filing published 11 Mar 2024 for Harpoon Therapeutics, Inc., €449.7M.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Merck & Co., Inc.: trading record in brief
Merck & Co., Inc. is a declared insider at 6 companies; the most frequent names are BeOne Medicines Ltd., CapForce Inc. and NGM Biopharmaceuticals Inc. Over a trading history stretching from 8 February 2016 to 11 March 2024, the count stands at 11 filings.
The open-market record is one-sided, with 3 purchases worth €517.0M and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 2 share grants. So far in 2024, the count stands at 1 purchase and no sales.
In size, the median ticket on the buying side is €58.6M. No cluster: in 3 purchases, no other insider of the company bought within 30 days.
The latest filing, published on 11 March 2024, reports an open-market purchase of €449.7M in Harpoon Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Merck & Co., Inc.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 21,397,205 shares@ US$23.00100.0% of flowCommon Stock, par value $0.0001SEC:0000950170-24-029165:0Canonical exit: 9 Jun 2024 (T+90)
- 253,516,000 sharesCommon StockSEC:0000899243-21-022060:0
- 18,518,519 sharesOrdinary SharesSEC:0001635698-16-000062:0
- 5,128,205 sharesOrdinary SharesSEC:0001635698-16-000062:1
- 7,942,314 sharesOrdinary SharesSEC:0001635698-16-000062:2
5 of 5 declarations
